Cart
sales@molnova.com
Ulixertinib hydrochloride
CAS No. 1956366-10-1
Ulixertinib hydrochloride( —— )
Catalog No. M36325 CAS No. 1956366-10-1
Ulixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 59 | In Stock |
|
| 2MG | 33 | In Stock |
|
| 5MG | 53 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 25MG | 136 | In Stock |
|
| 50MG | 184 | In Stock |
|
| 100MG | 346 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUlixertinib hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionUlixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors.
-
DescriptionUlixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorERK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1956366-10-1
-
Formula Weight469.79
-
Molecular FormulaC21H23Cl3N4O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (212.86 mM; Ultrasonic ) H2O : 0.1 mg/mL (0.21 mM; Ultrasonic (<80°C))
-
SMILESClC1=C(C=2C=C(C(N[C@H](CO)C3=CC(Cl)=CC=C3)=O)NC2)C=C(NC(C)C)N=C1.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311.?
molnova catalog
related products
-
NMDA
N-Methyl-D-aspartic acid is an amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors.
-
LY-3214996
LY-3214996 is a novel potent, selective, orally active ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays.
-
Mogrol
Mogrol is a biometabolite of mogrosides. Mogrol acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.
